02 August 2018
Visiongain has launched a new pharma report Drug Delivery Technologies Market Report : Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies
By definition, drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in the human body. In this report, the term drug delivery technology encompasses the methods of enhancing the delivery of a drug through changes in drug formulation, the use of medical devices or through combination products. Combination products are combinations of drug-device, biologic-device, biologic-drug or all three components together in one entity. Combination products will continue to provide promising approaches to the delivery of various types of drugs that may come with different molecular formulations in the coming years.
Drug delivery technologies also include drug delivery systems together with the various time delivery technologies that may be involved. Examples of drug delivery systems include tablets, capsules and patches. There are six main submarkets of drug delivery technologies that contribute to the total drug delivery technologies market — oral, inhalable, injectable/implantable, transdermal, ocular and nasal/buccal — each providing beneficial delivery routes for a specific small or large molecule towards an intended target.
The lead analyst for this report says:
“The market for drug delivery technologies has experienced strong growth in recent years. In 2018, the global drug delivery technologies market is expected to reach a value of $217.7bn. Visiongain expects the growth to continue over the forecast period. The market will be boosted by the increasing number of biologics as they are inherently difficult to administer by traditional drug delivery methods. Visiongain also expects the use of vaccines with innovative delivery platforms such as nasal sprays and transdermal patches will expand significantly over the next decade.
The US maintained its dominance as the leading national market for drug delivery technologies in 2018. Developed countries such as Japan, Germany and France were also key markets for drug delivery technologies in the same year. However, as these markets become more saturated with the growing number of drug delivery technologies, this presents opportunities for fast-growing markets such as China and India — which will become attractive areas of investment for big pharma companies.”
The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. The report discusses products from leading companies in the market. Notable companies in the Drug Delivery Technology market include Alkermes, 3M, Skyepharma, Becton Dickinson and Company (BD), Antares Pharma, pSivida, Applied Pharma Research (APR), Ethypharm, Glycologic and NanoPass Technologies amongst others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth